Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
      • Doodle Gallery
      • Circulation Cover Doodle
        • → Blip the Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
      • Recently Published Guidelines
    • Bridging Disciplines
    • Circulation at Major Meetings
    • Special Themed Issues
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation Supplements
    • Cardiovascular Case Series
    • ECG Challenge
    • Hospitals of History
      • Brigham and Women's Hospital
      • Hartford Hospital
      • Hospital Santa Maria del Popolo, Naples, Italy
      • Instituto do Coração-INCOR (São Paulo, Brasil)
      • Minneapolis City Hospital
      • Parkland Hospital: Dallas, Texas
      • Pennsylvania Hospital, Philadelphia
      • Pitié-Salpêtrière Hospital
      • Royal Infirmary of Edinburgh, Scotland
      • Tufts Medical Center
      • University of Michigan
      • Uppsala University Hospital
      • Vassar Brothers Medical Center (Poughkeepsie, NY)
      • Wroclaw Medical University
      • Women's College Hospital, Toronto, Canada
      • Henry Ford Hospital, Detroit, Michigan
      • Instituto Nacional de Cardiología Ignacio Chávez – INCICh México City, México
      • Kuang-Tien General Hospital (Taichug, Taiwan)
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
      • Accepted Manuscripts
      • Revised Manuscripts
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Bridging Disciplines
    • Circulation at Major Meetings
    • Special Themed Issues
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation Supplements
    • Cardiovascular Case Series
    • ECG Challenge
    • Hospitals of History
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Brief Rapid Communication

Hyperhomocysteinemia

A Risk Factor for Ischemic Stroke in Children

Ingrid M. van Beynum, Jan A. M. Smeitink, Martin den Heijer, Maria T. W. B. te Poele Pothoff, Henk J. Blom
Download PDF
https://doi.org/10.1161/01.CIR.99.16.2070
Circulation. 1999;99:2070-2072
Originally published April 27, 1999
Ingrid M. van Beynum
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan A. M. Smeitink
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin den Heijer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria T. W. B. te Poele Pothoff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henk J. Blom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Background—Moderate hyperhomocysteinemia is a risk factor for arterial vascular disease and venous thrombosis in adults. We performed a case-control study to assess a possible relation between moderate hyperhomocysteinemia and ischemic stroke in Dutch children (age range, 0 to 18 years).

Methods and Results—We measured plasma total homocysteine levels (tHcy) in 45 patients with ischemic stroke and in 234 controls. Hyperhomocysteinemia was defined as a tHcy above the 95th percentile regression line for the respective age of the controls. Hyperhomocysteinemia was present in 8 (18%) of the 45 patients with ischemic stroke. The odds ratio was 4.4 (95% CI, 1.7 to 11.6).

Conclusions—We conclude that moderate hyperhomocysteinemia is a risk factor for ischemic stroke in children.

  • hyperhomocysteinemia
  • cerebral infarction
  • stroke
  • pediatrics

Cerebrovascular disease in childhood is relatively rare. The incidence for ischemic and hemorrhagic strokes together is 2.7 cases per 100 000 population per year.1 Despite extensive evaluation, an etiologic factor or associated conditions remain undetermined in from 20% to 50% of all stroke patients.2 3 Patients with classic homocystinuria, a rare inborn error due to cystathionine β-synthase deficiency, suffer from premature cardiovascular disease and venous thrombosis at a very young age.4 Over the last 2 decades, it has become evident that moderate hyperhomocysteinemia is an independent risk factor for arteriosclerosis, including stroke,5 6 as well as for venous thrombosis.7 These studies have all been performed in adults. Whether moderate hyperhomocysteinemia is a risk factor for arterial vascular disease or venous thrombosis in children is unknown.

We performed a case-control study to assess a possible association between moderate hyperhomocysteinemia and ischemic stroke in Dutch children.

Methods

In children with cerebrovascular disease, we analyzed blood samples for total homocysteine (tHcy) from January 1989 through December 1997. These samples were collected primarily for tHcy measurement. We included 45 patients with objectively confirmed episodes of ischemic stroke (30 boys and 15 girls). The diagnosis of stroke was radiologically confirmed by CT scan or MRI. If required, MR angiography or single photon emission computerized tomography (SPECT) was also performed. Hemiparesis was the most common presenting symptom (29 [64%] of 45 children). The medial cerebral artery (26 patients) and basal ganglia (14 patients) were predominantly affected. The exclusion criteria were overt liver and renal dysfunction, hormonal therapy, neoplastic disease, and closure defects such as cleft lip and spina bifida. Overall, we excluded 2 patients with neoplastic disease and 1 with overt renal dysfunction. Classic risk factors for vascular disease, such as smoking, diabetes, and hypertension, were not present in the patients. Cholesterol was not routinely examined.

The control group, recruited in 1997, consisted of 234 subjects (115 boys and 119 girls). Children of secondary school age served as healthy volunteers, whereas for ethical reasons, the younger children were recruited in a hospital setting. Information about medical history was obtained from medical records or by questionnaire. The same exclusion criteria were applied for the control group as for the patients.

Blood was drawn by venipuncture, and in the very young, blood obtained from capillaries was used. tHcy levels were determined in EDTA plasma by an automated high-performance liquid chromatography method with reverse-phase separation and fluorescent detection.8

Because of a sharp increase in tHcy with age, we calculated a 95th percentile regression line of tHcy against age. Hyperhomocysteinemia was defined as a concentration that exceeded this 95th percentile regression line for the respective age. ORs and 95% CIs were calculated to estimate the relative risk of hyperhomocysteinemia. ORs were calculated with a logistic regression model. Analyses were performed with the statistical package SPSS.

The protocol was approved by the local ethics committee.

Results

tHcy values plotted by age of individual patients and controls are shown in the Figure⇓. tHcy increased sharply with age for both sexes in patients and the control group. There was no apparent difference between girls and boys except that in adolescence, tHcy tended toward higher levels in boys than in girls.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

tHcy concentrations plotted against age for control subjects (A) and patients with ischemic stroke (B). Linear regression line at 50th percentile, tHcy=7.05+0.2135×age; at 95th percentile, tHcy=11.429+0.2135×age.

Patients with stroke had a median age at the time of blood sampling of 1.8 years (range, 0 to 15.7 years), and controls were 8.6 years of age (range, 0 to 19.3 years). Therefore, all data had to be corrected for age. The highest incidence of cerebrovascular disease in childhood is predominantly in the very young, but cerebrovascular disease can occur at any age, as previously published.2 The median time between onset of symptoms and homocysteine determination was 0.1 year (range, 0 to 11.9 years). The median tHcy level was 8.5 mmol/L (range, 5.0 to 77 mmol/L) for the patients and 9.1 mmol/L (range, 4.3 to 20.0 mmol/L) for the controls.

Among the patients with ischemic stroke, 8 (18%) of 45 versus 11 (5%) of 234 in the control group had a tHcy level above the age-corrected cutoff points of homocysteine concentration. The OR for ischemic stroke was 4.4 (95% CI, 1.7 to 11.6). ORs for different age-corrected cutoff points of tHcy are shown in Table 1⇓ and demonstrate gradually increasing ORs at higher cutoff points in the highest quartile. A continuous dose-response relation seemed to be present above a threshold tHcy value of ≈70th percentile of controls. To evaluate a potential change in risk with increasing age of the child, we calculated ORs for 3 different age groups, balanced for number of cases (Table 2⇓). A trend toward an increase in the risk of ischemic stroke associated with hyperhomocysteinemia in increasingly older age groups is demonstrated.

View this table:
  • View inline
  • View popup
Table 1.

ORs for Different Age-Corrected Cutoff Points of Homocysteine Concentrations

View this table:
  • View inline
  • View popup
Table 2.

ORs for Ischemic Stroke With Hyperhomocysteinemia (95th Percentile of Age-Corrected Homocysteine Distribution) for Each Age Group

Creatinine concentration is known to be positively correlated with tHcy.9 Creatinine concentrations were determined in 178 controls and 29 patients. The calculated OR after adjustment for creatinine concentration remained virtually unchanged at 5.6 (95% CI, 0.9 to 34.2). The use of anticonvulsant drugs may influence homocysteine levels.9 In the present study, 15 children used anticonvulsant drugs for therapeutic or prophylactic reasons. The OR remained 3.1 (95% CI, 0.9 to 10.5) after exclusion of these 15 subjects.

Discussion

Studies about tHcy in children are not commonly reported. tHcy measurements performed in 41 macrobiotic infants showed evidently higher tHcy in these children, predominantly due to cobalamin deficiency.10 In 12 children with leukemia, tHcy levels varied during different stages of chemotherapy treatment.11 A Norwegian study12 among 8- to 12-year-old children found that a modest elevation in tHcy was related to premature cardiovascular death in their male relatives and may account in part for the contribution of family history to risk of cardiovascular disease. Recently, Vilaseca et al13 screened for hyperhomocysteinemia in selected pediatric patients, including children who had suffered a stroke. They found higher tHcy levels compared with age-matched reference values, which supports our findings. However, no subsequent analysis on this raw data was performed, and both children with ischemic infarct and hemorrhage were included, whereas only an association between occlusive vascular disease and hyperhomocysteinemia has been found.

In the present study, moderate hyperhomocysteinemia was related to a 4-fold increased risk for ischemic cerebrovascular disease in childhood. This OR is comparable to the relative risk found for ischemic vascular disease in adults.5 Although the pathogenesis of vascular disease due to hyperhomocysteinemia is unknown, this same risk for ischemic stroke in early childhood and in adults presumes a dysequilibrium of the coagulation-fibrinolysis status that results in an enhanced coagulation state rather than a prolonged, cumulative effect in arterial vessel wall, as is seen in hypercholesterolemia.

Among the patients, a 16-month-old boy had a very high tHcy level (77 mmol/L). It was suspected that he was homozygous for cystathionine β-synthase deficiency, and this diagnosis was confirmed by very low enzyme activity in cultured fibroblasts and molecular genetic analysis that showed homozygosity for the T833C mutation. After exclusion of this case, the adjusted OR remained virtually unchanged (3.8; 95% CI, 1.4 to 10.5). A vascular accident at this age in cystathionine β-synthase deficiency is rare, but cases have been described.5 Normalization of tHcy levels in vitamin B6–responsive cystathionine β-synthase–deficient patients with pyridoxine is effective in preventing complications such as arterial and venous thrombosis.5 Although blood and urine amino acid measurements are recommended in the pediatric textbooks, in our opinion they are still not performed routinely. On the basis of our findings, screening of plasma tHcy levels in children with vascular disease or venous thrombosis should be done at least to exclude rare inborn errors causing severe hyperhomocysteinemia.

Our study contributes to elucidation of idiopathic cases of ischemic cerebrovascular disease, indicating that moderate hyperhomocysteinemia is a common risk factor for ischemic stroke in children.

Acknowledgments

This study was supported in part by research grant D97.021 from the Dutch Heart Foundation. We would like to acknowledge Dr E. Rammeloo for her clinical contribution.

  • Received October 9, 1998.
  • Revision received February 26, 1999.
  • Accepted March 4, 1999.
  • Copyright © 1999 by American Heart Association

References

  1. ↵
    Broderick J, Talbot GT, Prenger E, Leach A, Brott T. Stroke in children within a major metropolitan area: the surprising importance of intracerebral hemorrhage. J Child Neurol. 1993;8:250–255.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Nicolaides P, Appleton RE. Stroke in children. Dev Med Child Neurol. 1996;38:172–180.
    OpenUrlPubMed
  3. ↵
    Mancini J, Girard N, Chabrol B. Ischemic cerebrovascular disease in children: retrospective study of 35 patients. J Child Neurol. 1997;12:193–199.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Gröbe H, Schmidt H, Schweitzer L. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985;37:1–31.
    OpenUrlPubMed
  5. ↵
    Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274:1049–1057.
    OpenUrlCrossRefPubMed
  6. ↵
    Selhub J, Jaques PF, Bostom AG, D’Agostino RB, Wilson PWF, Belanger AJ, O’Leary DH, Wolf PA, Schaeffer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;268:877–881.
  7. ↵
    den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759–762.
    OpenUrlCrossRefPubMed
  8. ↵
    Poele-Pothoff MTWB, van der Berg M, Franken DG, Boers GHJ, Jakobs C, Kroon IFI, Eskes TKAB, Trijbels JMF, Blom HJ. Three different methods for determination of total homocysteine in plasma. Ann Clin Biochem. 1995;32:218–220.
  9. ↵
    Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease and drug therapy. J Lab Clin Med. 1989;114:473–501.
    OpenUrlPubMed
  10. ↵
    Schneede J, Dagnelie PC, van Staveren WA, Vollset SE, Refsum H, Ueland PM. Methylmalonic acid and homocysteine in plasma as indicators of functional cobalamin deficiency in infants on macrobiotics diets. Pediatr Res. 1994;36:194–201.
    OpenUrlCrossRefPubMed
  11. ↵
    Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res. 1991;51:828–835.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Tonstad S, Refsum H, Sivertsen M, Christophersen B, Ose L, Ueland PM. Relation of total homocysteine and lipid levels in children to premature cardiovascular death in male relatives. Pediatr Res. 1996;40:47–52.
    OpenUrlCrossRefPubMed
  13. ↵
    Vilaseca MA, Moyano D, Artuch R, Ferrer I, Pineda M, Cardo E, Campistol J, Pavia C, Camacho JA. Selective screening for hyperhomocysteinemia in pediatric patients [Technical Brief]. Clin Chem. 1998;44:662–664.
    OpenUrlFREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation
April 27, 1999, Volume 99, Issue 16
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Hyperhomocysteinemia
    Ingrid M. van Beynum, Jan A. M. Smeitink, Martin den Heijer, Maria T. W. B. te Poele Pothoff and Henk J. Blom
    Circulation. 1999;99:2070-2072, originally published April 27, 1999
    https://doi.org/10.1161/01.CIR.99.16.2070

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Hyperhomocysteinemia
    (Your Name) has sent you a message from Circulation
    (Your Name) thought you would like to see the Circulation web site.
  • Share on Social Media
    Hyperhomocysteinemia
    Ingrid M. van Beynum, Jan A. M. Smeitink, Martin den Heijer, Maria T. W. B. te Poele Pothoff and Henk J. Blom
    Circulation. 1999;99:2070-2072, originally published April 27, 1999
    https://doi.org/10.1161/01.CIR.99.16.2070
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Epidemiology, Lifestyle, and Prevention
    • Epidemiology
  • Heart Failure and Cardiac Disease
    • Congenital Heart Disease

Circulation

  • About Circulation
  • Instructions for Authors
  • Circulation CME
  • Statements and Guidelines
  • Meeting Abstracts
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
200 Fifth Avenue, Suite 1020
Waltham, MA 02451
email: circ@circulationjournal.org
 

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured